全文获取类型
收费全文 | 202377篇 |
免费 | 28604篇 |
国内免费 | 6716篇 |
专业分类
耳鼻咽喉 | 1695篇 |
儿科学 | 1464篇 |
妇产科学 | 5149篇 |
基础医学 | 14822篇 |
口腔科学 | 2159篇 |
临床医学 | 16098篇 |
内科学 | 19263篇 |
皮肤病学 | 1359篇 |
神经病学 | 934篇 |
特种医学 | 5937篇 |
外国民族医学 | 253篇 |
外科学 | 28826篇 |
综合类 | 26283篇 |
现状与发展 | 39篇 |
一般理论 | 3篇 |
预防医学 | 9488篇 |
眼科学 | 111篇 |
药学 | 14492篇 |
131篇 | |
中国医学 | 4984篇 |
肿瘤学 | 84207篇 |
出版年
2024年 | 186篇 |
2023年 | 4215篇 |
2022年 | 5954篇 |
2021年 | 10480篇 |
2020年 | 10473篇 |
2019年 | 9474篇 |
2018年 | 9092篇 |
2017年 | 9529篇 |
2016年 | 10247篇 |
2015年 | 11855篇 |
2014年 | 17063篇 |
2013年 | 16907篇 |
2012年 | 13552篇 |
2011年 | 13742篇 |
2010年 | 9954篇 |
2009年 | 10210篇 |
2008年 | 10449篇 |
2007年 | 9776篇 |
2006年 | 8628篇 |
2005年 | 7072篇 |
2004年 | 5864篇 |
2003年 | 4876篇 |
2002年 | 4127篇 |
2001年 | 3804篇 |
2000年 | 3130篇 |
1999年 | 2567篇 |
1998年 | 1994篇 |
1997年 | 1730篇 |
1996年 | 1400篇 |
1995年 | 1482篇 |
1994年 | 1237篇 |
1993年 | 973篇 |
1992年 | 837篇 |
1991年 | 760篇 |
1990年 | 554篇 |
1989年 | 524篇 |
1988年 | 446篇 |
1987年 | 390篇 |
1986年 | 286篇 |
1985年 | 377篇 |
1984年 | 313篇 |
1983年 | 213篇 |
1982年 | 210篇 |
1981年 | 198篇 |
1980年 | 173篇 |
1979年 | 118篇 |
1978年 | 76篇 |
1977年 | 66篇 |
1976年 | 56篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
41.
42.
Mursheda Begum Grant Lewison Xiang Wang Philip D. Dunne Tim Maughan Richard Sullivan Mark Lawler 《International journal of cancer. Journal international du cancer》2023,152(3):470-479
The purpose of this study was to provide an evidence base for colorectal cancer research activity that might influence policy, mainly at the national level. Improvements in healthcare delivery have lengthened life expectancy, but within a situation of increased cancer incidence. The disease burden of CRC has risen significantly, particularly in Africa, Asia and Latin America. Research is key to its control and reduction, but few studies have delineated the volume and funding of global research on CRC. We identified research papers in the Web of Science (WoS) from 2007 to 2021, and determined the contributions of the leading countries, the research domains studied, and their sources of funding. We identified 62 716 papers, representing 5.7% of all cancer papers. This percentage was somewhat disproportionate to the disease burden (7.7% in 2015), especially in Eastern Europe. International collaboration increased over the time period in almost all countries except in China. Genetics, surgery and prognosis were the leading research domains. However, research on palliative care and quality-of-life in CRC was lacking. In Western Europe, the main funding source was the charity sector, particularly in the UK, but in most other countries government played the leading role, especially in China and the USA. There was little support from industry. Several Asian countries provided minimal contestable funding, which may have reduced the impact of their CRC research. Certain countries must perform more CRC research overall, especially in domains such as screening, palliative care and quality-of-life. The private-non-profit sector should be an alternative source of support. 相似文献
43.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):327-334.e2
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone. 相似文献
44.
目的 探讨情绪释放技术对改善乳腺癌术后化疗患者预期性悲伤的效果。方法 采用便利抽样法选取乳腺癌术后化疗患者60例为研究对象,采用随机数字表法将其分为对照组和干预组,各30例。对照组给予常规护理,干预组在对照组的基础上实施情绪释放干预疗法。比较干预前后2组心理痛苦程度和预期性悲伤得分水平。结果 干预后,干预组心理痛苦程度低于对照组(t=-17.930,P<0.001);预期性悲伤总分及各维度得分均低于对照组(P<0.001)。结论 对乳腺癌术后化疗患者应用情绪释放技术进行护理干预,可以减轻患者心理痛苦程度,降低患者预期性悲伤,值得临床推广应用。 相似文献
45.
《The Journal for Nurse Practitioners》2022,18(2):140-146
Early detection and improved treatments for breast cancer are increasing survival rates, thereby growing the number of survivors to almost 4 million in the United States. Continuing care after treatment is frequently provided in primary care. Evidence-based care includes a history review, physical examination, and imaging for recurrence and new cancers, along with health maintenance and health promotion. Additionally, survivors often experience long-term side effects from their disease and/or treatment, affecting health and quality of life. This article provides a synopsis of breast cancer treatment-related side effects and current evidence-based guidelines to assist the primary care provider caring for survivors. 相似文献
46.
介绍家庭适应的相关概念及起源,阐述家庭适应方面常用测量工具的发展历程、内容结构、适用人群、评分方法、信度与效度、应用现状等情况,以期能够指导临床工作者在实践过程中选择合适的家庭适应测量工具,旨在帮助研究者进一步开发适用于我国癌症生存者的特异性家庭适应测量工具。 相似文献
47.
胰腺癌新辅助化疗在临床应用愈加广泛。对于新辅助化疗后病人,腹腔镜胰十二指肠切除术是否安全有效,尚无研究。胰腺癌新辅助化疗后,肿瘤局部纤维结缔组织的炎症会导致缺乏良好组织间隙,解剖分离困难,因此微创手术的难点在于切除过程,而重建相对固定且成熟,很少会受到新辅助化疗的影响。新辅助化疗后,影像学评估肿瘤退缩效果往往不明显,更多的在于对肿瘤标记物等反应肿瘤生物学指标的控制。手术合并血管切除重建的比例相对较高,但得益于3D腹腔镜高清晰度和放大的手术视野,有利受侵犯血管的切除和重建。新辅助化疗后腹腔镜胰十二指肠切除术与开放手术相比,长期生存率是否存在差异,尚需前瞻性、大样本、多中心随机对照临床试验加以验证。 相似文献
48.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
49.
50.